Literature DB >> 12841548

Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

O Gimm, D J Marsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12841548     DOI： 10.1007/BF03345188

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  22 in total

1.  Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.

Authors:  O Nilsson; L E Tisell; S Jansson; H Ahlman; O Gimm; C Eng
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

2.  Deletion-insertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma.

Authors:  D J Marsh; S D Andrew; D L Learoyd; R Pojer; C Eng; B G Robinson
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

3.  A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.

Authors:  M Alemi; S D Lucas; J F Sällström; U Bergholm; G Akerström; E Wilander
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

4.  Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.

Authors:  I Ceccherini; B Pasini; F Pacini; M Gullo; I Bongarzone; C Romei; G Santamaria; I Matera; P Mondellini; L Scopsi; A Pinchera; M A Pierotti; G Romeo
Journal:  Oncogene       Date:  1997-05-29       Impact factor: 9.867

5.  Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases.

Authors:  R M Hofstra; T Stelwagen; R P Stulp; D de Jong; M Hulsbeek; E J Kamsteeg; A van den Berg; R M Landsvater; A Vermey; W M Molenaar; C J Lips; C H Buys
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

6.  A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.

Authors:  R M Hofstra; O Fattoruso; L Quadro; Y Wu; A Libroia; U Verga; V Colantuoni; C H Buys
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

7.  The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.

Authors:  D J Marsh; D McDowall; V J Hyland; S D Andrew; M Schnitzler; E L Gaskin; D F Nevell; T Diamond; L Delbridge; P Clifton-Bligh; B G Robinson
Journal:  Clin Endocrinol (Oxf)       Date:  1996-02       Impact factor: 3.478

8.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma.

Authors:  C Eng; L M Mulligan; D P Smith; C S Healey; A Frilling; F Raue; H P Neumann; R Pfragner; A Behmel; M J Lorenzo
Journal:  Genes Chromosomes Cancer       Date:  1995-03       Impact factor: 5.006

10.  A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.

Authors:  A Miyauchi; S Egawa; H Futami; K Kuma; T Obara; K Yamaguchi
Journal:  Jpn J Cancer Res       Date:  1997-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.